Covid-19: How AstraZeneca lost the vaccine PR war
Author:
Abstract
AstraZeneca’s covid-19 vaccine has rarely been out of the news—and the headlines show no signs of abating. Jacqui Wise explains how miscommunication and politics created a nightmare for the company and the global vaccination effortKeywords
This publication has 9 references indexed in Scilit:
- Covid-19: EMA defends AstraZeneca vaccine as Germany and Canada halt rolloutsBMJ, 2021
- Covid-19: AstraZeneca vaccine prevents 79% of symptomatic disease and 100% of severe disease, US study findsBMJ, 2021
- Covid-19: AstraZeneca vaccine is not linked to increased risk of blood clots, finds European Medicine AgencyBMJ, 2021
- Covid-19: WHO says rollout of AstraZeneca vaccine should continue, as Europe divides over safetyBMJ, 2021
- Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clotsBMJ, 2021
- Why did a German newspaper insist the Oxford AstraZeneca vaccine was inefficacious for older people—without evidence?BMJ, 2021
- Covid-19: South Africa pauses use of Oxford vaccine after study casts doubt on efficacy against variantBMJ, 2021
- Covid-19: Oxford vaccine is up to 90% effective, interim analysis indicates2020
- Covid-19: Oxford researchers halt vaccine trial while adverse reaction is investigated2020